环磷酰胺治疗转移性结直肠癌的II期研究。欧洲癌症研究与治疗组织临床筛查小组的一项试验。
Phase II study of cystemustine in metastatic colorectal carcinoma. A trial of the EORTC Clinical Screening Group.
作者信息
Kerbrat P, Adenis A, Rebattu P, Roche H, Chevallier B, Chollet P, Krakowski I, Lentz M A, Fumoleau P
机构信息
Centre Eugène Marquis, Rennes, France.
出版信息
Eur J Cancer. 1993;29A(11):1597-9. doi: 10.1016/0959-8049(93)90302-v.
PMID:8217367
Abstract
27 patients with metastatic colorectal carcinoma were treated, every 2 weeks, with 60 mg/m2 cystemustine, a new chloro-2-ethyl nitrosourea derivative. Haematological toxicity was the major side-effect including neutropenia and thrombocytopenia. We did not observe any complete or partial response. Cystemustine, with this dose and this schedule, has no activity in colorectal cancer.
摘要
27例转移性结直肠癌患者每2周接受一次60mg/m²的西氮芥治疗，西氮芥是一种新型氯-2-乙基亚硝基脲衍生物。血液学毒性是主要副作用，包括中性粒细胞减少和血小板减少。我们未观察到任何完全缓解或部分缓解。按照此剂量和疗程，西氮芥对结直肠癌无活性。
Zotero 插件